Financial health
- Operating income covered interest expense 63× in the latest year, up from -23.4× 2 years ago.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
NSRX Financials Nasus Pharma Ltd
3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.2B | -$6M | 0.0% | -0.4% | -$5M | — | $1M |
| 2024 | — | -$2M | — | — | — | — | $284000 |
| 2023 | — | -$1M | — | — | — | — | $193000 |
Valuation over time
How the market has priced NSRX against its own fundamentals since 2025-08 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 0.1× (Dec '25) to 0.0× (Jun '26).
P/S
Frequently asked questions
Is NSRX growing its revenue and profit?
See the revenue and net-income charts above for Nasus Pharma Ltd's multi-year trend.
How much debt does NSRX have?
As of FY2025, Nasus Pharma Ltd reported — of total debt against $1M of cash; operating income covered interest expense 63×.
What is NSRX's profit margin?
In FY2025, gross margin was —, operating margin -0.4%, and net margin -0.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.